Clinical and radiographic effects of ascorbic acid-augmented platelet-rich fibrin versus platelet-rich fibrin alone in intra-osseous defects of stage-III periodontitis patients: a randomized controlled clinical trial

Abstract Aim To assess platelet-rich fibrin (PRF) with ascorbic acid (AA) versus PRF in intra-osseous defects of stage-III periodontitis patients. Methodology Twenty stage-III/grade C periodontitis patients, with ≥ 3 mm intra-osseous defects, were randomized into test (open flap debridement (OFD)+AA/PRF; n = 10) and control (OFD+PRF; n = 10). Clinical attachment level (CAL; primary outcome), probing pocket depth (PPD), gingival recession depth (RD), full-mouth bleeding scores (FMBS), full-mouth plaque scores (FMPS), radiographic linear defect depth (RLDD) and radiographic defect bone density (RDBD) (secondary-outcomes) were examined at baseline, 3 and 6 months post-surgically. Results OFD+AA/PRF and OFD+PRF demonstrated significant intragroup CAL gain and PPD reduction at 3 and 6 months (p < 0.001). OFD+AA/PRF and OFD+PRF showed no differences regarding FMBS or FMPS (p > 0.05). OFD+AA/PRF demonstrated significant RD reduction of 0.90 ± 0.50 mm and 0.80 ± 0.71 mm at 3 and 6 months, while OFD+PRF showed RD reduction of 0.10 ± 0.77 mm at 3 months, with an RD-increase of 0.20 ± 0.82 mm at 6 months (p < 0.05). OFD+AA/PRF and OFD+PRF demonstrated significant RLDD reduction (2.29 ± 0.61 mm and 1.63 ± 0.46 mm; p < 0.05) and RDBD-increase (14.61 ± 5.39% and 12.58 ± 5.03%; p > 0.05). Stepwise linear regression analysis showed that baseline RLDD and FMBS at 6 months were significant predictors of CAL reduction (p < 0.001). Conclusions OFD+PRF with/without AA significantly improved periodontal parameters 6 months post-surgically. Augmenting PRF with AA additionally enhanced gingival tissue gain and radiographic defect fill. Clinical relevance PRF, with or without AA, could significantly improve periodontal parameters. Supplementing PRF with AA could additionally augment radiographic linear defect fill and reduce gingival recession depth.

Download Full-text

Efficacy of a New-generation Platelet-rich Fibrin in the Treatment of Periodontal Intrabony Defects: a Randomized Clinical Trial

10.21203/rs.3.rs-525471/v1 ◽

2021 ◽

Author(s):

Boroka Klara Csifo-Nagy ◽

Eleonora Solyom ◽

Vera Lili Bognar ◽

Annamaria Nevelits ◽

Ferenc Dori

Keyword(s):

Positive Impact ◽

Test Group ◽

Gingival Recession ◽

Control Group ◽

Intrabony Defects ◽

Pocket Depth ◽

Platelet Rich Fibrin ◽

Registration Number ◽

Enamel Matrix Derivatives ◽

New Generation

Abstract Background: The aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivatives (EMD). Methods: Thirty (30) intrabony defects of 18 patients (9 males, 9 females) were randomly treated with A-PRF+ (test, n=15) or EMD (control, n=15). The following clinical parameters were recorded at baseline and 6 months after surgery: pocket depth (PD), gingival recession (GR) and clinical attachment level (CAL). After debridement the intrabony defects were filled with A-PRF+ in the test group, respectively with EMD in the control group, and fixed with sutures to ensure wound closure and stability.Results: Both treatment methods resulted in statistically significant PD reductions, respectively CAL gains six months post-operatively. No statistically significant differences were found between the two groups as the mean CAL gain was 2.33±1.58 mm in the A-PRF+ group, respectively 2.60±1.18 mm in the EMD group (p < 0.001).Conclusion: Within the limits of this study the new-generation platelet-rich fibrin seems to be as clinically effective as EMD in the surgical treatment of intrabony defects. Treatment with A-PRF+ or EMD resulted in reliable clinical outcomes. The use of A-PRF+ as a human autologous product can give a positive impact on periodontal healing.Clinical Relevance: A-PRF+ may be suitable for the treatment of intrabony periodontal defects. Trial registration number (TRN): NCT04404374 (ClinicalTrials.gov ID)Date of registration: 19.05.2020., retrospectively registered

Download Full-text

Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planning in the treatment of stage III periodontitis: a pilot randomized controlled clinical trial

BMC Oral Health ◽

10.1186/s12903-020-01276-3 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Alicia Morales ◽

Rafael Contador ◽

Joel Bravo ◽

Paola Carvajal ◽

Nora Silva ◽

...

Keyword(s):

Clinical Trial ◽

Lactobacillus Rhamnosus ◽

Stage Iii ◽

Treatment Modalities ◽

Controlled Clinical Trial ◽

Clinical Effects ◽

Pocket Depth ◽

Clinical Attachment Loss ◽

Probing Pocket Depth

Abstract Background The aim of this triple-blind placebo-controlled parallel-arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with stage III periodontitis. Methods Forty-seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; (1) placebo (n = 15), (2) probiotics (n = 16) and (3) antibiotics-azithromycin (n = 16). The participants were monitored at baseline, 3, 6, 9 and 12 months after therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation (PI) were evaluated. Results All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD and PI (p < 0.012) irrespective of the treatment modality and without significant differences between the groups. Probiotics and azithromycin showed no added benefit in terms of CAL. While the placebo (p = 0.002) and the antibiotic-azithromycin (p = 0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant reduction of CAL at 12 months follow-up (p = 0.003). The number of sites and teeth with PPD ≥ 5, ≥ 6 and ≥ 7 mm were significantly reduced in all groups at 12 months follow-up (p < 0.025) irrespective of the treatment regime and without significant differences between the groups. Conclusion The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the treatment of stage III periodontitis. The benefits of these two treatment regimes as an adjunct to SRP remain unclear. Trial registration NCT02839408, 10/28/2017, Clinicaltrial.gov.

Download Full-text

Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial

BMC Oral Health ◽

10.1186/s12903-021-01925-1 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Boróka Klára Csifó-Nagy ◽

Eleonóra Sólyom ◽

Vera Lili Bognár ◽

Annamária Nevelits ◽

Ferenc Dőri

Keyword(s):

Positive Impact ◽

Test Group ◽

Gingival Recession ◽

Enamel Matrix Derivative ◽

Control Group ◽

Intrabony Defects ◽

Pocket Depth ◽

Platelet Rich Fibrin ◽

Registration Number ◽

New Generation

Abstract Background The aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivative (EMD). Methods Thirty (30) intrabony defects of 18 patients (9 males, 9 females) were randomly treated with A-PRF+ (test, n = 15) or EMD (control, n = 15). The following clinical parameters were recorded at baseline and 6 months after surgery: pocket depth (PD), gingival recession (GR) and clinical attachment level (CAL). After debridement the intrabony defects were filled with A-PRF+ in the test group, respectively with EMD in the control group, and fixed with sutures to ensure wound closure and stability. Results Both treatment methods resulted in statistically significant PD reductions, respectively CAL gains six months post-operatively. No statistically significant differences were found between the two groups as the mean CAL gain was 2.33 ± 1.58 mm in the A-PRF+ group, respectively 2.60 ± 1.18 mm in the EMD group (p < 0.001). Conclusion Within the limits of this study the new-generation platelet-rich fibrin seems to be as clinically effective as EMD during surgical treatment of intrabony defects. Treatment with A-PRF+ or EMD resulted in reliable clinical outcomes. The use of A-PRF+ as a human autologous product can give a positive impact on periodontal healing. Clinical Relevance A-PRF+ may be suitable for the treatment of intrabony periodontal defects. Trial registration number (TRN) NCT04404374 (ClinicalTrials.gov ID).

Download Full-text

Platelet Rich Fibrin (PRF) along with Coronally Repositioned Flap (CRF) compared with that of CRF alone in the management of isolated Miller class-I gingival recession defects: A non-randomized controlled clinical trial

IP International Journal of Periodontology and Implantology ◽

10.18231/j.ijpi.2021.008 ◽

2021 ◽

Vol 6 (1) ◽

pp. 42-48

Author(s):

Tony Kurien J ◽

Baiju RM ◽

Vivek Narayan

Keyword(s):

Clinical Trial ◽

Gingival Recession ◽

Class I ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Platelet Rich Fibrin ◽

Randomized Controlled

Download Full-text

Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planing in the treatment of periodontitis stage III: A pilot randomized controlled clinical trial

10.21203/rs.3.rs-45864/v2 ◽

2020 ◽

Author(s):

Alicia Morales ◽

Rafael Contador ◽

Joel Bravo ◽

Paola Carvajal ◽

Nora Silva ◽

...

Keyword(s):

Clinical Trial ◽

Stage Iii ◽

Treatment Modalities ◽

Controlled Clinical Trial ◽

Clinical Effects ◽

Scaling And Root Planing ◽

Pocket Depth ◽

Clinical Attachment Loss ◽

Root Planing

Abstract Background: The aim of this triple- blind placebo- controlled parallel- arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with stage III periodontitis.Methods: Forty-seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; 1) placebo (n=15), 2) probiotics (n=16) and 3) antibiotics-azithromycin (n=16). The participants were monitored at baseline, 3, 6, 9 and 12 months after therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation (PI) were evaluated. Results: All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD and PI (p<0.012) irrespective of the treatment modality and without significant differences between the groups. Probiotics and azithromycin showed no added benefit in terms of CAL. While the placebo (p=0.002) and the antibiotic-azithromycin (p=0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant reduction of CAL at 12 months follow-up (p=0.003). The number of sites and teeth with PPD ≥5, ≥6 and ≥7mm were significantly reduced in all groups at 12 months follow-up (p<0.025) irrespective of the treatment regime and without significant differences between the groups. Conclusion: The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the treatment of stage III periodontitis. The benefits of these two treatment regimes as an adjunct to SRP remain unclear.

Download Full-text

Evaluation of the effect of dose-dependent platelet-rich fibrin membrane on treatment of gingival recession: a randomized, controlled clinical trial

Journal of Applied Oral Science ◽

10.1590/1678-7757-2017-0278 ◽

2018 ◽

Vol 26 (0) ◽

Cited By ~ 2

Author(s):

Rana Culhaoglu ◽

Levent Taner ◽

Berceste Guler

Keyword(s):

Clinical Trial ◽

Gingival Recession ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Platelet Rich Fibrin ◽

Randomized Controlled ◽

Dose Dependent ◽

Fibrin Membrane

Download Full-text

Platelet-Rich Fibrin in the Treatment of Periodontal Bone Defects

The Journal of Contemporary Dental Practice ◽

10.5005/jp-journals-10024-1546 ◽

2014 ◽

Vol 15 (3) ◽

pp. 372-375 ◽

Cited By ~ 7

Author(s):

Aravindhan T Ranganathan

Keyword(s):

Bone Graft ◽

Platelet Rich Plasma ◽

Clinical Results ◽

Bone Defects ◽

Pocket Depth ◽

Hydroxy Apatite ◽

Posterior Teeth ◽

Platelet Rich Fibrin ◽

Osseous Defects ◽

Periodontal Bone Defects

ABSTRACT Background Periodontitis is characterized by the formation of true pockets, bone loss and attachment loss. Various techniques have been attempted in the past to truly regenerate the lost periodontal structures, albeit with variable outcome. In this evolution, the technique being tried out widely is the use of platelet rich concentrates, namely platelet-rich fibrin (PRF). Case description In this report, we present a case of surgical treatment of osseous bone defects namely two walled crater and dehiscence treated in posterior teeth with autologously prepared platelet rich fibrin mixed with hydroxy apatite bone graft and PRF in the form of a membrane. Conclusion Our results showed clinical improvements in all the clinical parameters postoperatively namely the pocket depth reduction and gain in attachment level and hence, PRF can be used alone or in combination with the bone graft to yield successful clinical results in treating periodontal osseous defects. Clinical significance Platelet-rich fibrin is an effective alternative to platelet-rich plasma (PRP) in reconstructing bone defects. How to cite this article Ranganathan AT, Chandran CR. Platelet-Rich Fibrin in the Treatment of Periodontal Bone Defects. J Contemp Dent Pract 2014;15(3):372-375.

Download Full-text

Clinical Effects of Probiotic or Azithromycin as an Adjunct to Scaling and Root Planing in the Treatment of Periodontitis Stage III: A Pilot Randomized Controlled Clinical Trial

10.21203/rs.3.rs-45864/v1 ◽

2020 ◽

Author(s):

Alicia Morales ◽

Rafael Contador ◽

Joel Bravo ◽

Paola Carvajal ◽

Nora Silva ◽

...

Keyword(s):

Clinical Trial ◽

Stage Iii ◽

Treatment Modalities ◽

Controlled Clinical Trial ◽

Clinical Effects ◽

Scaling And Root Planing ◽

Pocket Depth ◽

Clinical Attachment Loss ◽

Root Planing

Abstract Background The aim of this triple- blind placebo- controlled parallel- arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with periodontitis stage III. Methods Forty-seven systemically healthy participants with periodontitis stage III were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; 1) placebo (n = 15), 2) probiotics (n = 16) and 3) antibiotics-azithromycin (n = 16). The participants were monitored at baseline, 3, 6, 9 and 12 months after therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation (PI) were evaluated. Results All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD and PI (p < 0.012) irrespective of the treatment modality and without significant differences between the groups. Probiotics and azithromycin showed no added benefit in terms of CAL. While the placebo (p = 0.002) and the antibiotic-azithromycin (p = 0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant reduction of CAL at 12 months follow-up (p = 0.003). The number of sites and teeth with PPD ≥ 5, ≥6 and ≥ 7 mm were significantly reduced in all groups at 12 months follow-up (p < 0.025) irrespective of the treatment regime and without significant differences between the groups. Conclusion The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the treatment of periodontitis stage III. The benefits of these two treatment regimes as an adjunct to SRP remain unclear.

Download Full-text